Ixekizumab

Ixekizumab is an IgG4 type monoclonal antibody that binds with high affinity and specifically to interleukin 17A (both IL-17A and IL-17A/F), a pro-inflammatory cytokine involved in the pathogenesis of autoimmune diseases. In rheumatology, ixekizumab is primarily used for the treatment of psoriatic arthritis, a chronic inflammatory arthritis associated with psoriasis.

The main indication of ixekizumab in rheumatology is:

  • Psoriatic arthritis: Ixekizumab is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). It can be used as monotherapy or in combination with conventional DMARDs.

Ixekizumab is administered by subcutaneous injection and dosing frequency varies depending on the specific condition being treated. It has been shown to improve signs and symptoms, inhibit structural damage, and improve physical function in patients with psoriatic arthritis. As other biologic medications, ixekizumab may increase the risk of infections and other adverse effects, so its use should be carefully monitored by a rheumatologist or other qualified healthcare provider. Regular monitoring of patients receiving ixekizumab may include laboratory monitoring for changes in blood counts and liver function tests.